Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 0.61 |
| ▸ | CDK1 | P06493 | 5/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.57 |
| ▸ | CDK4 | P11802 | 2/20 | 0.57 |
| ▸ | CDKL1 | Q00532 | 1/20 | 0.57 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1448376 | 1.00 | CDK2 (0.61) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL1448611 | 0.97 | CDK2 (0.64) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL1448629 | 0.93 | CDK2 (0.63) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL1447436 | 0.91 | KCNH2 (0.69) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL1446871 | 0.90 | CDK2 (0.67) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL1448097 | 0.88 | CDK2 (0.71) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL1447605 | 0.88 | CDK2 (0.75) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL1447688 | 0.87 | KCNH2 (0.73) | CDK2CDK1KCNH2CDK4CDKL1 | |
| SCHEMBL1447718 | 0.87 | CDK2 (0.77) | CDK2CDK1KCNH2CDK4 | |
| SCHEMBL1447867 | 0.86 | CDK2 (0.62) | CDK2CDK1KCNH2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220088010-A1 | Co-Administration of inhibitors to produce insulin producing gut cells | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088010-A1 | Co-Administration of inhibitors to produce insulin producing gut cells | IAPP, GPR119, FOXO1 | CDK2 1502/4885CDK1 644/4885KCNH2 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.